GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Dividend Payout Ratio

Nyrada (ASX:NYR) Dividend Payout Ratio : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Dividend Payout Ratio?

Nyrada's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Nyrada's Dividend Payout Ratio or its related term are showing as below:


ASX:NYR's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-04), the Dividend Yield % of Nyrada is 0.00%.

Nyrada's Dividends per Share for the months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Nyrada Dividend Payout Ratio Historical Data

The historical data trend for Nyrada's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Dividend Payout Ratio Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Dividend Payout Ratio
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Dividend Payout Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Nyrada's Dividend Payout Ratio

For the Biotechnology subindustry, Nyrada's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nyrada's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Nyrada's Dividend Payout Ratio falls into.



Nyrada Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Nyrada's Dividend Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Jun. 2023 )/ EPS without NRI (A: Jun. 2023 )
=0/ -0.05
=N/A

Nyrada's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ 0.001
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyrada (ASX:NYR) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Nyrada Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Nyrada's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada (ASX:NYR) Business Description

Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines